209 related articles for article (PubMed ID: 30759785)
21. PET Imaging of Dll4 Expression in Glioblastoma and Colorectal Cancer Xenografts Using (64)Cu-Labeled Monoclonal Antibody 61B.
Zhou B; Wang H; Liu R; Wang M; Deng H; Giglio BC; Gill PS; Shan H; Li Z
Mol Pharm; 2015 Oct; 12(10):3527-34. PubMed ID: 26288060
[TBL] [Abstract][Full Text] [Related]
22. Development of high-specific-activity (68)Ga-labeled DOTA-rhenium-cyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors.
Cantorias MV; Figueroa SD; Quinn TP; Lever JR; Hoffman TJ; Watkinson LD; Carmack TL; Cutler CS
Nucl Med Biol; 2009 Jul; 36(5):505-13. PubMed ID: 19520291
[TBL] [Abstract][Full Text] [Related]
23. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
24. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
25. Radiosynthesis and biological evaluation of 68Ga-labeled colchicine conjugates.
Satpati D; Korde A; Sarma HD; Banerjee S
Cancer Biother Radiopharm; 2014 Aug; 29(6):251-6. PubMed ID: 24983126
[TBL] [Abstract][Full Text] [Related]
26. In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.
D'Alessandria C; Pohle K; Rechenmacher F; Neubauer S; Notni J; Wester HJ; Schwaiger M; Kessler H; Beer AJ
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):953-963. PubMed ID: 26497698
[TBL] [Abstract][Full Text] [Related]
27. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
28. Development of Radiopharmaceuticals for NPY Receptor-5 (Y5) Nuclear Imaging in Tumors by Synthesis of Specific Agonists and Investigation of Their Binding Mode.
Bodin S; Peuker LC; Jestin E; Alves ID; Velasco V; Ait-Arsa I; Schollhammer R; Lamare F; Vimont D; MacGrogan G; Hindié E; Beck-Sickinger AG; Morgat C
Bioconjug Chem; 2023 Nov; 34(11):2014-2021. PubMed ID: 37556437
[TBL] [Abstract][Full Text] [Related]
29.
Wei X; Liu Z; Zhao Z
Hell J Nucl Med; 2019; 22(1):78-79. PubMed ID: 30968863
[TBL] [Abstract][Full Text] [Related]
30. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
[TBL] [Abstract][Full Text] [Related]
31. Biological evaluation of integrin α
Lambidis E; Chen CC; Lumen D; Sánchez AIF; Sarparanta M; Cheng RH; Airaksinen AJ
Eur J Pharm Sci; 2023 Jan; 180():106336. PubMed ID: 36403717
[TBL] [Abstract][Full Text] [Related]
32. Development of a (68)Ga-peptide tracer for PET GnRH1-imaging.
Zoghi M; Jalilian AR; Niazi A; Johari-Daha F; Alirezapour B; Ramezanpour S
Ann Nucl Med; 2016 Jul; 30(6):400-8. PubMed ID: 27083468
[TBL] [Abstract][Full Text] [Related]
33. Development of Novel
Poret B; Desrues L; Bonin MA; Pédard M; Dubois M; Leduc R; Modzelewski R; Decazes P; Morin F; Vera P; Castel H; Bohn P; Gandolfo P
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32204509
[TBL] [Abstract][Full Text] [Related]
34. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of 68Ga-bis-DOTA-PA as a potential agent for positron emission tomography imaging of necrosis.
Prinsen K; Cona MM; Cleynhens BJ; Li J; Vanbilloen H; Dyubankova N; Lescrinier E; Ni Y; Bormans GM; Verbruggen AM
Nucl Med Biol; 2013 Aug; 40(6):816-22. PubMed ID: 23915800
[TBL] [Abstract][Full Text] [Related]
37. Manipulating the In Vivo Behaviour of
Imberti C; Adumeau P; Blower JE; Al Salemee F; Baguña Torres J; Lewis JS; Zeglis BM; Terry SYA; Blower PJ
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098299
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and radiolabelling of DOTA-linked glutamine analogues with ⁶⁷,⁶⁸Ga as markers for increased glutamine metabolism in tumour cells.
Pellegrini PA; Howell NR; Shepherd RK; Lengkeek NA; Oehlke E; Katsifis AG; Greguric I
Molecules; 2013 Jun; 18(6):7160-78. PubMed ID: 23783455
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and evaluation of a novel 68Ga-labeled DOTA-benzamide derivative for malignant melanoma imaging.
Kim HJ; Kim DY; Park JH; Yang SD; Hur MG; Min JJ; Yu KH
Bioorg Med Chem Lett; 2012 Aug; 22(16):5288-92. PubMed ID: 22796183
[TBL] [Abstract][Full Text] [Related]
40. [(68) Ga]-HP-DO3A-nitroimidazole: a promising agent for PET detection of tumor hypoxia.
Wu Y; Hao G; Ramezani S; Saha D; Zhao D; Sun X; Sherry AD
Contrast Media Mol Imaging; 2015; 10(6):465-72. PubMed ID: 26122548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
